Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics

Luis E. Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, Rory M. Shallis, Leora Boussi, Andrius Zucenka, Sylvain Garciaz, Rebecca P. Bystrom, Daniel J. DeAngelo, Richard M. Stone, Marlise R. Luskin, Jacqueline S. Garcia, Eric S. Winer, Kelly Ling, Evan C. Chen, Martha Wadleigh, Guillaume Berton, Eytan M. Stein, Aaron D. Goldberg, Lourdes Mendez, Amer M. Zeidan, David A. Sallman, Shai Shimony, Maximilian Stahl

Open source

DOI: 10.1016/j.bneo.2026.100201
Published: 2026-05
Container: Blood Neoplasia
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.bneo.2026.100201,
  title = {Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics},
  author = {Luis E. Aguirre and Jan Philipp Bewersdorf and Yiwen Liu and Rory M. Shallis and Leora Boussi and Andrius Zucenka and Sylvain Garciaz and Rebecca P. Bystrom and Daniel J. DeAngelo and Richard M. Stone and Marlise R. Luskin and Jacqueline S. Garcia and Eric S. Winer and Kelly Ling and Evan C. Chen and Martha Wadleigh and Guillaume Berton and Eytan M. Stein and Aaron D. Goldberg and Lourdes Mendez and Amer M. Zeidan and David A. Sallman and Shai Shimony and Maximilian Stahl},
  year = {2026},
  journal = {Blood Neoplasia},
  doi = {10.1016/j.bneo.2026.100201},
  url = {https://doi.org/10.1016/j.bneo.2026.100201}
}

RIS

TY  - JOUR
TI  - Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics
AU  - Luis E. Aguirre
AU  - Jan Philipp Bewersdorf
AU  - Yiwen Liu
AU  - Rory M. Shallis
AU  - Leora Boussi
AU  - Andrius Zucenka
AU  - Sylvain Garciaz
AU  - Rebecca P. Bystrom
AU  - Daniel J. DeAngelo
AU  - Richard M. Stone
AU  - Marlise R. Luskin
AU  - Jacqueline S. Garcia
AU  - Eric S. Winer
AU  - Kelly Ling
AU  - Evan C. Chen
AU  - Martha Wadleigh
AU  - Guillaume Berton
AU  - Eytan M. Stein
AU  - Aaron D. Goldberg
AU  - Lourdes Mendez
AU  - Amer M. Zeidan
AU  - David A. Sallman
AU  - Shai Shimony
AU  - Maximilian Stahl
PY  - 2026
JO  - Blood Neoplasia
DO  - 10.1016/j.bneo.2026.100201
UR  - https://doi.org/10.1016/j.bneo.2026.100201
ER  -

APA

Aguirre, L. E., Bewersdorf, J. P., Liu, Y., Shallis, R. M., Boussi, L., Zucenka, A., Garciaz, S., Bystrom, R. P., DeAngelo, D. J., Stone, R. M., Luskin, M. R., Garcia, J. S., Winer, E. S., Ling, K., Chen, E. C., Wadleigh, M., Berton, G., Stein, E. M., Goldberg, A. D., Mendez, L., Zeidan, A. M., Sallman, D. A., Shimony, S., & Stahl, M. (2026). Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics. Blood Neoplasia. https://doi.org/10.1016/j.bneo.2026.100201

Source records

crossref · retrieved 2026-09-26T13:31:32.321Z